Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korean Government Task Force Uncovers Illegal Rebates From Device Firms

This article was originally published in PharmAsia News

Executive Summary

With the help of state prosecutors, Korea’s health ministry expands the scope of anti-rebate surveillance to the medical device sector.

You may also be interested in...

Korean Government Launches Strongest-ever Drive To Root Out Rebates

SEOUL - In the strongest ever all-out government crackdown on rebates between hospital doctors and pharmaceutical companies, the Korean government established a joint task force at a Seoul Prosecution Office that it hopes will add teeth to better enforce anti-rebate laws implemented last November

South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law

SEOUL - South Korea's Ministry of Health and Welfare outlined detailed provisions to implement a new "anti-rebate law," which will enable courts to punish both contributors and receivers of rebates. Passed overwhelmingly by South Korea's National Assembly on April 28, the law goes into effect Nov. 28, and will be enforced by the ministry.Under the new regulations, pharmas will be able to offer "sample" drugs as long as they are offered the "minimum packing unit," said the ministry, adding that they will also be able to offer minimal amounts of drugs and research fees to those conducting clinical trials

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts